Navigation Links
DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium
Date:3/25/2009

Thirteen Abstracts Will Be Featured at Annual Kidney Care Meeting

EL SEGUNDO, Calif., March 25 /PRNewswire/ -- DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney failure and disease (CKD), in conjunction with DaVita Clinical Research(R), today announced that company representatives will present thirteen abstracts at the National Kidney Foundation's 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 in Nashville, TN. The meeting is a platform for the nation's leading renal health care providers to learn about new developments in the field of nephrology and CKD care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

Allen R. Nissenson MD, Chief Medical Officer at DaVita says, "DaVita is continuing to lead the renal community in generating important new knowledge to improve the outcomes for patients with kidney disease. This commitment to high quality clinical research is clearly evident in the thirteen abstracts being presented at the National Kidney Foundation meeting this year."

DaVita's top ten clinical initiatives for 2009 include: striving for reduction of first-year mortality rates and reducing catheter use. At this year's National Kidney Foundation Clinical Meeting, DaVita will focus on several key research initiatives in the areas of CKD, new incident dialysis patients, and integrated pharmacy management. Highlights from these scheduled presentations will include:

  • Improved Results in CKD Management: Recent data reveals superior outcomes in the areas of CKD and mortality, anemia, incident patient management and phosphorus and coronary artery calcification. DaVita researchers note a nearly 50 percent drop in one-year mortality in Detroit area, DaVita-managed CKD clinics compared to Renal Network 11 (12.8% vs. 22.6%);
  • Advances in Streamlining the Patient Onboarding Process: Data on DaVita's IMPACT(TM) (Incident Management of Patients, Actions Centered on Treatment) program - a pilot project implemented in 44 DaVita centers around the nation focusing on patient education and important clinical outcomes - demonstrates how this comprehensive approach reduces mortality of incident patients. Results showed a reduction in 90-day mortality nearly two percentage points lower (6.14% vs. 7.98%) among IMPACT versus nonIMPACT patients; and
  • Integrated Pharmacy Management Impacts Clinical Outcomes: DaVita Rx(sm) pharmacy program removes common access barriers for patients, such as transportation and access to the medications they require. Researchers observed significantly improved clinical outcomes in DaVita Rx patients compared to non-DaVita Rx patients.

In addition to DaVita's research initiatives on CKD, IMPACT and DaVita Rx, the following is a complete list of abstracts scheduled for presentation:

      -- Title:  First Year Dialysis Mortality in Patients Previously Enrolled
         in a Structured Chronic Kidney Disease (CKD) Program
         Authors:  Joel M. Topf(1), Robert Provenzano(2), Steve Wilson(3),
         Ajay Chokshi(3) and Amy Bogan(3)

         (1)St. John Hospital & Medical Center, Detroit, Michigan,(2)Office of
         the Chief Medical Officer, DaVita Inc., El Segundo, CA, (3)DaVita
         Inc., El Segundo, CA

      -- Title:  Analysis of Potassium Profiles Among Hemodialysis (HD)
         Patients
         Authors:  John Robertson, Debbie Benner, Ronald Levine
         DaVita Inc., El Segundo, CA

      -- Title:  Day-To Day, Week-To-Week, and Day-Of-Week Variation in Tests
         of Anemia and Iron Status in Hemodialysis Patients
         Authors:  David B. Van Wyck(1), Harry Alcorn(1), Resmi Gupta(2)

         (1)DaVita, Inc., El Segundo, CA, (2)Vital Systems, Inc.,
         Schaumburg,IL

      -- Title:  Benefit of Using Visual Teaching Tools for Phosphorus Control
         in Hemodialysis Unit
         Authors:  Carol Allen
         DaVita Inc., Selma, CA

      -- Title:  Binder Consumption as a Function of Time: A Linear Model for
         Lowering Elevated Phosphorus Levels by Improving Binder Timing
         Authors:  Mark A. Livingston
         DaVita Inc., Warren, MI

      -- Title:  Mortality of 5-Year Time-Averaged Low Serum Calcium <8.5
         mg/dL in Subgroups of Hemodialysis (HD) Patients
         Authors:  Jessica E Miller(1), Elani Streja(1), Csaba P Kovesdy(2),
         David Van Wyck(3), Allen R. Nissenson(3), and Kamyar Kalantar-
         Zadeh(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; and (3)DaVita Inc, El Segundo, CA

      -- Title:  Association of Serum Alkaline Phosphatase and Coronary Artery
         Calcification in Hemodialysis Patients
         Authors:  Ronney Shantouf(1), Mehdi Rambod(1), Csaba P Kovesdy(2),
         Naser Ahmadi(1), Allen R. Nissenson(3), Matthew J Budoff(1), and
         Kamyar Kalantar-Zadeh(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; and (3)DaVita Inc, El Segundo, CA

      -- Title:  Mortality-Predictability of Weight Gain vs Weight Loss Over 6
         Months in Maintenance Hemodialysis (MHD) Patients
         Authors:  Kamyar Kalantar-Zadeh(1), Elani Streja(1), Csaba P
         Kovesdy(2), Allen R. Nissenson(3), and Joel D Kopple(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; (3)DaVita Inc, El Segundo, CA

      -- Title:  Improved Outcomes Post Enrollment in High Touch, Tailored
         Pharmacy--Meeting the Patients' Need
         Authors:  Maricela Lara-Nevarez(1), Meredith Mathews(1), Chad
         Lennox(2)

         (1)DaVita Inc., El Segundo, CA (2)Dialysis Patient Citizens,
         Washington, DC

      -- Title:  Characteristics and Clinical Outcomes of US Pediatric
         Dialysis Patients at A Large Dialysis Provider
         Authors:  Allen R. Nissenson, Joe Weldon, and Joan Fieldhouse
         DaVita Inc., El Segundo, CA

      -- Title:  Incident Management of Hemodialysis Patients: Managing the
         First 90 Days
         Authors:  John Robertson, Pooja Goel, Grace Chen, Ronald Levine,
         Debbie Benner, and Amy Burdan
         DaVita Inc., El Segundo, CA

      -- Title:  Body Mass Index (BMI) and Survival in Polycystic Kidney
         Disease (PKD) Hemodialysis (HD) Patients
         Authors:  Elani Streja(1), Csaba P Kovesdy(2), Jenni Jing(1), Allen
         R. Nissenson(3), and Kamyar Kalantar-Zadeh(1)

         (1)Harold Simmons Center for Kidney Disease Research and
         Epidemiology, LABioMed at Harbor-UCLA, Torrance, CA; (2)Salem VA
         Medical Center, Salem, VA; (3)DaVita Inc., El Segundo, CA

      -- Title:  Comparing Death Risk of Polycystic Kidney Disease (PKD)
         Hemodialysis (HD) Patients to Non-PKD HD Patients
         Authors:  Elani Streja(1), Allen R. Nissenson(3), David VanWyck(3),
         Csaba P Kovesdy(2), and Kamyar Kalantar- Zadeh(1)

         (1)Harold Simmons Center & Cardiology, LABioMed at Harbor-UCLA,
         Torrance, CA; (2)Salem VA Medical Center, Salem, VA; (3)DaVita Inc.,
         El Segundo, CA

DaVita, IMPACT and DaVita Rx are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,400 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 110,000 patients. As part of DaVita's commitment to building a healthy, caring community, DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. For more information about DaVita, its kidney education materials and its community programs, please visit www.davita.com.


'/>"/>
SOURCE DaVita Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
2. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
3. DaVita Abstracts Highlight Latest Research Developments at Annual Dialysis Conference
4. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
5. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
6. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
7. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
8. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
9. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... 15, 2017  AOTI Inc. announced today that its fully owned ... recently opened a New York City Office in Yonkers, ... unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This new ... for Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable ... Advanced ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made their ... to an ambitious venture that conjoined the passions of an NBA star, a Liberty ... Liberty community. These shoes will save lives from the rampant infections transmitted through the ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... launch of this summer’s edition of “Vision & Hearing,” advocating for active, healthy ... campaign focuses on resources available for individuals with hearing impairments and shares the ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez ... consultations to communities throughout the greater DC region, is inaugurating a “New Leash ... rescuing local animals and training them to be companions for veterans in need. ...
(Date:8/18/2017)... ... 18, 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset ... of Campagna Academy in a charity drive to provide for at-risk children and teens ... Campagna Academy is a nonprofit organization that has offered critical programs to at-risk and ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active ... hormone replacement therapy and integrative medicine, has become a frontrunner for people seeking ... as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 ...
Breaking Medicine News(10 mins):